Director Declaration

    June 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
    that Flemming Ornskov, MD, MPH, Chief Executive Officer of the Company, was
    appointed to the Board of Directors of Waters Corporation on June 22, 2017.

    This notification is to satisfy the Company's obligations under LR 9.6.14R of
    the UK Listing Rules.

    Stephen Williams
    Deputy Company Secretary

    For further information please contact:

    Investor Relations                                                           
                                                                                 
    Ian Karp                        ikarp@shire.com            +1 781 482 9018   
                                                                                 
    Robert Coates                   rcoates@shire.com          +44 1256 894874   
                                                                                 
    Media                                                                        
                                                                                 
    Lisa Adler                      lisa.adler@shire.com       +1 617 588 8607   
                                                                                 
    Debbi Ford                      debbi.ford@shire.com       +1 617 949 9083   

    NOTES TO EDITORS

    About Shire

    Shire is the leading global biotechnology company focused on serving people
    with rare diseases. We strive to develop best-in-class products, many of which
    are available in more than 100 countries, across core therapeutic areas
    including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage
    Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary
    Angioedema; and a growing franchise in Oncology.

    Our employees come to work every day with a shared mission: to develop and
    deliver breakthrough therapies for the hundreds of millions of people in the
    world affected by rare diseases and other high-need conditions, and who lack
    effective therapies to live their lives to the fullest.

    www.shire.com